Zeria Pharmaceutical Co., Ltd.

Equities

4559

JP3428850006

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-04-26 am EDT 5-day change 1st Jan Change
2,059 JPY +0.54% Intraday chart for Zeria Pharmaceutical Co., Ltd. +2.29% +2.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints CI
Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3 MT
Japanese Shares End Firmer on Friday on BoJ Policy Outlook MT
Zeria Pharmaceutical Books Higher Fiscal H1 Attributable Profit on Loss Provision Reversal MT
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of Fiscal Year Ending March 31, 2024, Payable on December 1, 2023 CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Zeria Pharmaceutical’s Attributable Profit Up 12.1% in Fiscal Q1 on Absence of Forex Losses MT
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2024 CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for the Six Months of 2024 and the Fiscal Year Ending March 31, 2024 CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Second Quarter of 2024 CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022. CI
Zeria Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2022, has closed with 263,900 shares, representing 0.6% for ¥545.29 million. CI
Zeria Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2024 CI
Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2023, Payable on June 30, 2023; Provides Second Quarter Dividend Guidance for the Full Year Ending March 31, 2024 CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2024 CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022. CI
Zeria Pharmaceutical's Attributable Profit Soars 48% in Fiscal Nine Months MT
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023 CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023 CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022. CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023 CI
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of the Year Ending March 31, 2023, Payable on December 1, 2022 CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023 CI
Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till May 12, 2023. CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022. CI
Chart Zeria Pharmaceutical Co., Ltd.
More charts
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2,059 JPY
Average target price
2,810 JPY
Spread / Average Target
+36.47%
Consensus
  1. Stock Market
  2. Equities
  3. 4559 Stock
  4. News Zeria Pharmaceutical Co., Ltd.
  5. Zeria Pharmaceutical Books Higher Fiscal H1 Attributable Profit on Loss Provision Reversal